CPOX

Across TCGA pan-cancer cohorts, CPOX Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CPOX data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CPOX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPOX expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, LUSC, and READ are the cancer types where CPOX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.051	0.684	<.001	24	view →
LUSC	OS	Median	All	0.173	0.724	.012	15	view →
READ	OS	Median	II,III,IV	0.287	0.829	.008	14	view →
UCEC	DFS	Median	II,III,IV	0.915	0.436	.028	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CPOX–BLCA (OS)

Open the BLCA breakdown →